Form 4: Eledon Pharmaceuticals Director Jan Hillson Acquires Stock Options and Restricted Stock Units

Director Jan Hillson of Eledon Pharmaceuticals acquired stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.

Summary

• Jan Hillson, a director at Eledon Pharmaceuticals, was granted stock options to purchase 30,870 shares of common stock at an exercise price of $4.04 per share.
• These options vest 100% on January 10, 2026, and expire on January 10, 2035.
• Additionally, Hillson received 3,430 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock upon settlement.
• These RSUs also vest 100% on January 10, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a director, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

The granting of stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize and retain key personnel, particularly directors.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard forms of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting period of one year is fairly typical, aligning with industry norms for incentivizing long-term performance.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based compensation strategies for their directors and executives.

Stakeholder Impact

• The granting of stock options and RSUs to a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
• Employees may also view this positively as it indicates the company's commitment to incentivizing key personnel.

Key Dates

Keywords

Eledon Pharmaceuticals, stock options, restricted stock units, director, insider trading, equity compensation, vesting